![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 17, 14910-14915, April 26, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Medicine, San Francisco General Hospital,
University of California, San Francisco, California 94143
Received for publication, October 6, 2001, and in revised form, December 14, 2001
Papain-family cysteine proteases of the malaria
parasite Plasmodium falciparum, known as falcipains, are
hemoglobinases and potential drug targets. Available data suggest that
papain-family proteases require prodomains for correct folding into
functional conformations. However, in prior studies of falcipain-2, an
Escherichia coli-expressed construct containing only a
small portion of the prodomain refolded efficiently, suggesting that
this enzyme differs in this regard from other papain-family enzymes. To
better characterize the determinants of folding for falcipain-2, we
expressed multiple pro- and mature constructs of the enzyme in E. coli and assessed their abilities to refold. Mature falcipain-2
refolded into active protease with very similar properties to those of
proteins resulting from the refolding of proenzyme constructs. Deletion
of a 17-amino acid amino-terminal segment of the mature protease
yielded a construct incapable of correct folding, but inclusion of this
segment in trans allowed folding to active falcipain-2. The
prodomain was a potent, competitive, and reversible inhibitor of mature
falcipain-2 (Ki 10 Malaria remains one of the most important infectious
diseases in the world. Plasmodium falciparum, the most
virulent human malaria parasite, is responsible for hundreds of
millions of illnesses and more than one million deaths each year (1).
Because available antimalarial agents are limited by drug resistance,
toxicity, and cost, new drugs, ideally directed against new targets,
are urgently needed (2). Among promising drug targets are proteases that hydrolyze hemoglobin during the erythrocytic stage of infection and thereby provide amino acids for parasite protein synthesis (3).
Cysteine protease inhibitors blocked parasite hemoglobin hydrolysis and
development in vitro (4) and cured
Plasmodium-infected mice (5), suggesting that plasmodial
cysteine proteases are appropriate drug targets. The best characterized
cysteine proteases of P. falciparum are the papain-family
enzymes falcipain-2 (6) and falcipain-3 (7). Each of these proteases
cleaves hemoglobin under the acidic conditions of the plasmodial food
vacuole, the site of hemoglobin hydrolysis, and they are likely the
principal targets of antimalarial cysteine protease inhibitors.
In initial studies of the in vitro refolding of
Escherichia coli-expressed falcipain-2 and falcipain-3,
constructs including the mature proteases and only short (35 and 33 amino acid, respectively) carboxyl-terminal portions of the prodomains
folded into active enzymes (6-8). These results were surprising,
because the prodomains of papain-family proteases have previously been
deemed essential for correct folding (9-11). Mature falcipain-2 and
falcipain-3 contain an unusual amino-terminal segment that is not seen
in any other described papain-family enzymes. We hypothesized that the
amino-terminal extension of falcipain-2 plays a role in protein folding. To determine the roles of the falcipain-2 prodomain and amino-terminal extension of the mature domain in folding, we evaluated the abilities of multiple falcipain-2 constructs to refold into active
protease. We found that the falcipain-2 prodomain is not required for
folding, that folding is mediated by the amino-terminal extension, and
that, as is the case with other proteases, the prodomain is a potent
inhibitor of mature falcipain-2.
Materials--
Benzyloxycarbonyl-Phe-Arg-7-amino-4-methyl
coumarin (Z-Phe-Arg-AMC)1 was
from Bachem, Z-Leu-Arg-AMC was from Peptides International, and
Z-Phe-Arg-fluoromethyl ketone (Z-Phe-Arg-FMK) was a gift from Dr.
Robert Smith (Prototek). Restriction endonucleases and Vent DNA
polymerase were from New England Biolabs. Oligonucleotides were
synthesized at the Biomolecular Resource Center, University of
California, San Francisco. The synthetic peptide was from Genemed Synthesis. All other reagents were from Sigma or as mentioned in the text.
Polymerase Chain Reaction and Sequencing--
All DNA fragments
were amplified from the pTOP-FP2 plasmid (6) using Vent DNA Polymerase
and the primers mentioned below. The sequence of each construct was
confirmed by DNA sequencing at the Biomolecular Resource Center,
University of California, San Francisco.
Cloning, Expression, and Refolding of Falcipain-2
Constructs--
Four constructs coding for the falcipain-2 mature
domain (FP2) and various lengths of the prodomain (
To determine the best refolding buffer for each of the constructs, 176 combinations of 11 different buffers were tested by a microtiter plate
refolding assay (8). Refolding buffers contained 100 mM
Tris-Cl, 1 mM EDTA, pH 9.0 (A) plus 500 mM
L-arginine (B), 250 mM L-arginine + 5% glycerol (C), 30% glycerol (D), 250 mM L-arginine plus 30% glycerol (E), 20% sucrose (F), 250 mM L-arginine plus 20% sucrose (G), 1 M KCl (H), 1 M KCl plus 20% glycerol (I), 1 M KCl plus 20% sucrose (J), and 16 different combinations
of reduced (GSH) and oxidized (GSSG) glutathione as described
previously (8). For the refolding assay, 3 µl of denatured-reduced
protein (150 pmol in 8 M urea, 20 mM Tris-Cl,
200 mM imidazole, 10 mM dithiothreitol (DTT),
pH 8.0) was added to 297 µl of each ice-cold refolding buffer and
incubated at 4 °C for 20 h. Refolding was measured as the
hydrolysis of Z-Leu-Arg-AMC by 25 µl of each refolding reaction (in
350 µl of 100 mM sodium acetate, 50 µM
Z-Leu-Arg-AMC, 10 mM DTT, pH 5.5) assayed fluorometrically,
as previously described at room temperature for 30 min (8).
For large scale refolding, equal amounts (100 nmol) of each
denatured-reduced protein were diluted 100-fold in 200 ml of the optimal refolding buffer for each protein, containing 1 mM
each GSH and GSSG (buffers B for Amino-terminal Sequencing and Substrate SDS-PAGE--
For
amino-terminal sequencing, purified active products of Expression, Purification, and Refolding of Extension-deleted
Falcipain-2 Constructs--
To generate Progress of Refolding--
Samples (150 pmol) of
denatured-reduced recombinant proteins (in 8 M urea, 20 mM Tris-Cl, 200 mM imidazole, 10 mM
DTT, pH 8.0) were diluted 100-fold in 297 µl of ice-cold refolding
buffer containing 1 mM each of reduced and oxidized
glutathione (buffers B for Expression and Purification of Propeptides--
DNA
fragments coding for propeptides with ( Refolding in the Presence of Propeptide
Constructs--
Refolding of extension-deleted mature falcipain-2
(dFP2) alone or with different concentrations of prodomain constructs
( Effect of the Prodomain on the Catalytic Properties of
Falcipain-2--
Protease concentrations were determined by
active-site titration with Z-Phe-Arg-FMK. Constant amounts (1.0 nM with Z-Leu-Arg-AMC and 2.0 nM with
Z-Phe-Arg-AMC) of enzyme were incubated with different concentrations
of substrate, hydrolysis over time was assessed fluorometrically
(excitation 355 nm, emission 460 nm) for 15 min (Z-Leu-Arg-AMC) or 30 min (Z-Phe-Arg-AMC) in 100 mM sodium acetate, 10 mM DTT, pH 5.5, at room temperature, and the kinetic
constants Km and VMAX were
determined by non-linear regression using Prism (GraphPad Software).
Inhibition of Falcipain-2 by the Prodomain--
To refold
prodomain Unusual Features of Plasmodial Cysteine Proteases--
Falcipain-2
and falcipain-3 are fairly typical papain-family proteases, but they
share some unusual features, including large prodomains, a putative
type II membrane-spanning region near the amino terminus, and some
unique inserts in the mature protease sequence (6, 7). Most relevant
for this study, the two plasmodial proteases lack the typical
papain-family mature protease cleavage site, where cleavage occurs
immediately upstream of the sequence XP, where X
represents a nonpolar amino acid about 25 amino acids upstream of the
catalytic cysteine (16) (Fig. 1). The
conserved proline is seen in nearly all known papain-family proteases
other than falcipain-2 and falcipain-3. Determination of the
amino-terminal sequences of native mature falcipain-2 and processed
recombinant falcipain-2 and falcipain-3 showed that these two enzymes
contain an amino-terminal extension, with an additional 17 amino acids in falcipain-2 and 26 amino acids in falcipain-3 relative to other papain-family proteases (Fig. 1). The sequences of the two plasmodial amino-terminal extensions are 47% identical and do not show
significant identity with any other protein sequences in available data
bases.
The Falcipain-2 Protease Domain Refolds without Its
Prodomain--
To investigate the role of the falcipain-2 prodomain,
we expressed four constructs including mature falcipain-2 with
different portions of the prodomain ( Prodomain Does Not Alter the Catalytic Behavior of
Falcipain-2--
It has recently been shown that alterations in
prodomains can result in differential properties of mature proteases
that are identical in sequence but have been processed from different
proenzyme constructs (17). To determine whether this "memory"
phenomenon was evident in falcipain-2, we compared catalytic properties
of the four active proteases generated from different
falcipain-2 constructs. The four proteases cleaved peptide substrates
with very similar kinetics (Table
I). Thus, the falcipain-2
prodomain does not appear to impart folding characteristics on the
mature protease that impact on catalytic activity.
The Amino-terminal Extension of Mature Falcipain-2 Is Essential for
Folding--
Considering the lack of a requirement for the prodomain
for folding of mature falcipain-2, we considered the role of the
unusual amino-terminal extension of this mature protease. Three
constructs from which the 17-amino acid extension was deleted were
expressed in E. coli (Fig. 4,
A and C), purified, and refolded. Proenzyme constructs from which the 17-amino acid extension was deleted ( The Amino-terminal Extension Can Mediate Folding in
Trans--
To determine whether the amino-terminal extension must be
covalently linked to the remainder of the mature protease for folding, prodomain constructs with ( The Prodomain Is a Potent Inhibitor of Falcipain-2--
In
addition to their roles as mediators of folding, the prodomains of many
papain-family (20, 21) and other (22, 23) proteases are potent
inhibitors of their cognate proteases, but it is not clear if the
folding and inhibitory functions of these domains are linked. It was of
interest to determine whether the falcipain-2 prodomain retained an
inhibitory function independent of folding activity. The inhibition of
falcipain-2 by the prodomain was compared for the active products of
four different constructs ( We have characterized folding determinants of the P. falciparum cysteine protease falcipain-2 and shown that, unlike
other studied papain-family proteases, falcipain-2 does not require its
prodomain for folding. Rather, falcipain-2 utilizes an unusual amino-terminal peptide to mediate folding. Although the falcipain-2 prodomain differs from other papain-family enzymes in this regard, it
shares another function in that it is a potent inhibitor of the mature protease.
Molecular chaperones mediate folding of many proteins (24). A subset of
chaperones, including the proforms of many serine (11, 25-27) and
cysteine (9, 10) proteases, act intramolecularly by mediating folding
of the cognate mature protein before processing and removal of the
chaperone domain. Our results identify a novel intramolecular
chaperone-like function for the amino-terminal extension of
falcipain-2. It is described as chaperone-like, because unlike true
chaperones, it remains bound to the mature protease.
A role in folding for small amino-terminal peptides has previously been
hypothesized but not, to our knowledge, identified (28). It is likely
that many other proteins utilize small intramolecular peptides to
mediate folding, in particular proteins that lack prodomains and those,
such as falcipain-2 and some other proteases (e.g. trypsin,
chymotrypsin, and cathepsin D), that do not require their prodomains
for folding to the active enzymes (29-31). Of note, the prodomain of
falcipain-2 acts as a potent inhibitor of the mature protease, but it
does not affect the rate or efficiency of protease folding or impact on
the catalytic properties of the mature protease.
The unusual folding properties of falcipain-2 are probably
shared by other plasmodial cysteine proteases. Falcipain-3 (but not
falcipain-1) shares the presence of an unusual sequence at the amino
terminus of the mature protease domain (7). In addition, a chimeric
protein in which the amino-terminal extension of falcipain-2 was
replaced by the corresponding region of falcipain-3 refolded with very
similar efficiency to that of
falcipain-2.2 Similar
sequences are also seen in homologous proteases of murine malaria
parasites3 but not in any
other reported cysteine proteases. Thus, the unusual folding properties
of a subset of the falcipains appear to be required due to a specific
feature of the biology of malaria parasites.
Why has a plasmodial cysteine protease developed an unusual
intramolecular control of protein folding? We hypothesize that this
architecture may have been generated to allow the protease to perform
two quite different cellular functions. First, falcipain-2 cleaves
hemoglobin in the acidic P. falciparum food vacuole (4, 6).
Second, the protease appears to be responsible for the hydrolysis of
erythrocyte cytoskeletal proteins that is probably required to allow
the egress of mature parasites from the erythrocyte. A role for
falcipain-2 in the hydrolysis of cytoskeletal proteins is supported by
the observation that cysteine protease inhibitors block the rupture of
erythrocytes by mature malaria parasites (32, 33), the identification
of P. falciparum cysteine protease activity that cleaves the
erythrocyte cytoskeletal proteins ankyrin and protein 4.1 (34), and the
demonstration that this activity is identical to that of
recombinant falcipain-2 (35).
To access hemoglobin, falcipain-2 is likely transported to the parasite
food vacuole by vesicular trafficking from the cytostome organelle
after insertion into the parasite plasma membrane, as has also been
proposed for aspartic plasmodial proteases (36). To access the
erythrocyte cytoskeleton, we propose that falcipain-2 is cleaved from
the plasma membrane by limited autohydrolysis or the action of
exogenous proteases. This process likely occurs at the cytostome, the
plasmodial organelle through which erythrocyte cytosol transits into
the parasite, and where the parasite plasma membrane appears to be in
direct apposition with erythrocyte cytosol (37). If this cleavage into
erythrocyte cytosol liberates truncated, incompletely folded
falcipain-2, the parasite may have evolved an intramolecular system for
protease folding that is independent of the prodomain to allow the
elaboration of hydrolytic activity against cytoskeletal targets. This
model must take into account the need for control of falcipain-2
activity in the erythrocyte, presumably via inhibition by the free
falcipain-2 prodomain or exogenous cysteine protease inhibitors such as
cystatins. In any event, it explains the unique need in malaria
parasites for a cysteine protease that can mediate its folding after
cleavage of the prodomain.
More generally, our data show that inhibitory and folding functions can
be independent in papain-family enzymes. This independent control of
enzyme inhibition and folding may well be a common feature of
proteases, including those that may utilize different portions of the
prodomain for the two functions. Furthermore, our results identify the
use of a small internal peptide to direct folding of a mature protease
and suggest that many other proteins may incorporate similar systems in
which internal sequences provide mediation of protein folding.
We thank Jiri Gut and Belinda Lee for
technical assistance and Ajay Singh, James McKerrow, Fred Cohen, Joel
Ernst, and William Welch for helpful advice.
*
This work was supported by National Institutes of Health
Grants AI35800 and RR01081.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, February 4, 2002, DOI 10.1074/jbc.M109680200
2
P. S. Sijwali, unpublished data.
3
A. Singh, unpublished data.
The abbreviations used are:
Z-Phe-Arg-AMC, benzyloxycarbonyl-Phe-Arg-7-amino-4-methylcoumarin;
Z-Leu-Arg-AMC, benzyloxycarbonyl-Leu-Arg-7-amino-4-methylcoumarin;
Ni-NTA, nickel
nitrilotriacetic acid;
DTT, dithiothreitol.
Folding of the Plasmodium falciparum Cysteine
Protease Falcipain-2 Is Mediated by a Chaperone-like Peptide and Not
the Prodomain*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
10 M).
Our results identify a chaperone-like function of an amino-terminal segment of mature falcipain-2 and suggest that protease inhibition, but
not the mediation of folding, is a principal function of the falcipain-2 prodomain.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
188FP2,
89FP2,
and
35FP2) were PCR-amplified using the following primers (bold
italics indicate restriction endonuclease cleavage sites):
188FP2, 1F (5'-TTATTGGATCCTACTCCAAATTCTAGAAAAAGTG-3') and
1R (5'-TGACAAGCTTATTCAATTAATGGAATGAATGCATCAGTACC-3');
89FP2, 2F (5'-GATAAGGATCCCTTAATGAATAATGCAGAAC-3') and 1R;
35FP2, 3F (5'-ATAGTTGGATCCGGGAAAGAATTAAACAGATTTGCC-3') and
1R; and FP2, 4F (5'-TATTTAGGATCCCAAATGAATTATGAAGAAG-3') and 1R. The DNA fragments were digested with BamHI and
HindIII, ligated into
BamHI-HindIII-digested pQE-30 (FP2 and
35FP2;
Qiagen) or pRSET-B (
89FP2 and
188FP2; Invitrogen) plasmids and used to transform M15(pREP4) (for pQE) or AD(DE3)pLys (for pRSET) E. coli. Both pRSET-B and pQE-30 expression vectors add His-tag
fusions at the amino terminus of the foreign proteins that allow
one-step purification of recombinant proteins by
nickel-nitrilotriacetic acid (Ni-NTA) chromatography. Expression was
induced with isopropyl
-D-thiogalactopyranoside, and
expressed proteins were purified by Ni-NTA chromatography under
denaturing conditions as previously described (8).
188FP2 and
89FP2
were further purified by binding to a Q-Sepharose column (Amersham
Biosciences) and elution with a step gradient of NaCl in 8 M urea, 20 mM Tris-Cl, pH 8.0.
188FP2, C for
89FP2, and E for
35FP2 and FP2) and incubated at 4 °C for 20 h. Insoluble
protein was removed using a 0.22-µm membrane. Each refolding reaction
was concentrated to 20 ml, brought to pH 5.8 and 5 mM DTT
at room temperature for 1.5 h (1 h for
35FP2 and FP2), the pH
was raised to 6.25, the protein was applied to a Q-Sepharose column,
and active protease was eluted using a gradient of 1 M NaCl
in 20 mM bis-Tris, pH 6.25. Elution fractions containing
protease activity (indicated by Z-Leu-Arg-AMC hydrolysis) were
combined, concentrated to 1-2 ml, and diluted with an equal volume of
glycerol for storage. Quantities of unfolded expressed proteases were
estimated by the Bradford assay (12). To estimate recovery of active
protease, enzyme concentrations were determined by active site
titration with Z-Phe-Arg-FMK (13) before (
35FP2 and FP2) or after
(
188FP2 and
89FP2) purification.
188FP2,
89FP2,
35FP2, and FP2 were electrophoresed in a 12% SDS-polyacrylamide gel, transferred to an Immobilon-PSQ
membrane (Millipore), stained with Coomassie Blue, excised, and sequenced at the Protein and Nucleic Acid Facility, Stanford University Medical Center. For substrate SDS-PAGE, protease samples were mixed
with non-reducing SDS-PAGE sample buffer and electrophoresed in a 12%
SDS-polyacrylamide gel copolymerized with 0.1% gelatin. The gel was
washed twice with 2.5% Triton X-100 for 30 min each at room
temperature, incubated overnight at 37 °C in 100 mM
sodium acetate, 10 mM DTT, pH 5.5, and then stained with
Coomassie Blue.
188dFP2 and
89dFP2,
proregions of
188dFP2 (1F and 2R
(5'-ATGATCATCTAATAAATATTTAGAATTCTTTAATGG3-')) and
89dFP2 (2F and 2R) were amplified and then recombined with an extension deleted mature fragment (5F
(5'-TCTAAATATTTATTAGATGATCATGCAGCTTACGACTGG-3') and 1R) by
the overlap extension PCR method (overlapping primer regions are
underlined) (14). The coding sequence for extension-deleted mature
falcipain-2 (dFP2) was amplified using primers 6F
(5'-GAGGAGAAGAGGATCCCGATCATGCAGCTTACGACTGG-3') and 1R.
The DNA fragments were digested with BamHI and
HindIII, ligated in pRSET-B, and expressed in AD(DE3)pLys
E. coli. Proteins were purified from isopropyl
-D-thiogalactopyranoside-induced E. coli
cells by Ni-NTA chromatography as described above.
188dFP2 and
89dFP2 were further purified under denaturing conditions with
Q-Sepharose as described above. Refolding of
188dFP2,
89dFP2, and
dFP2 was assessed in the 176 buffers described above.
188FP2 and
188dFP2; C for
89FP2 and
89dFP2; E for
35FP2, FP2 and dFP2) and incubated at 4 °C. At
multiple time points, 15 µl of each refolding reaction was incubated
in 325 µl of 100 mM sodium acetate, 10 mM
DTT, pH 5.5, at room temperature for 25 min to allow processing, 10 µl of Z-Leu-Arg-AMC was added (final concentration 50 µM), and fluorescence, representing protease activity,
was monitored continuously for 10 min at room temperature (8).
188P17 and
89P17) or without (
188P and
89P) the 17-amino acid
extension were PCR-amplified using primers (1F and 3R
(5'-GTAAGCTGAAGCTTAGAAATTTTCTTCTCCTCTATA-3')) for
188P17, 2F and 3R for
89P17, 1F and 4R
(5'-CATAATTCAAAGCTTATAATAAATATTTAGAATTCTTTAATGGT-3') for
188P, and 2F and 4R for
89P). Each of the DNA fragments was
digested with BamHI and HindIII, ligated into
pRSET-B, and expressed in AD(DE3)pLys cells. Propeptides were purified
from isopropyl
-D-thiogalactopyranoside-induced
AD(DE3)pLys cells by Ni-NTA chromatography under denaturing
conditions as described above. To purify further,
Ni-NTA-purified propeptides were bound to a SP-Sepharose column
(Amersham Biosciences) and eluted by a step gradient of NaCl in 8 M urea, 20 mM Tris-Cl, pH 8.0.
188P17,
89P17,
188P, or
89P; molar
ratio of dFP2:prodomain constructs 1:1-1:3) or a synthetic peptide
(molar ratio of dFP2:peptide 1:1-1:50) identical to the falcipain-2
amino-terminal extension was studied in 11 refolding buffers (described
above; each containing 1 mM each GSH and GSSG). An equal
amount of mature falcipain-2 (FP2) was also refolded in buffer E. For
each refolding reaction, 3-µl aliquots containing 150 pmol of
denatured reduced recombinant protein(s) were added to 297 µl of
ice-cold refolding buffer, samples were incubated at 4 °C for
20 h to allow refolding, 25 µl of each refolding reaction was
added to 315 µl of 100 mM sodium acetate, 10 mM DTT, pH 5.5, at room temperature for 25 min to allow
processing, and refolding to active enzyme was assessed as relative
hydrolysis of Z-Leu-Arg-AMC over 30 min.
188P for inhibition studies, the denatured protein was
100-fold diluted (final protein concentration 15-20 µg/ml) in 100 mM Tris-Cl, 1 mM EDTA, 500 mM
L-arginine-HCl, pH 7.5, incubated at 4 °C for 20 h,
and concentrated (using a 10-kDa cut-off membrane, Millipore) to 10 ml.
Insoluble protein was removed using a 0.22-µm syringe filter.
Different concentrations of
188P were preincubated with 0.96 nM falcipain-2 derived from 4 different constructs in 100 mM sodium acetate, 10 mM DTT, pH 5.5, for 10 min at room temperature. The substrate Z-Leu-Arg-AMC (4 µM; ~2-fold below Km) was added, and
fluorescence was continuously measured for 10 min. Pseudo-first order
conditions were assumed (substrate hydrolysis was shown to be
10%) (15). The results were plotted as
(Vo/Vi)
1 versus I, where Vo is the
uninhibited rate, Vi the rate in the presence of the
inhibitor, and I is the concentration of inhibitor. From
this plot, the Ki,app was determined (slope = 1/Ki,app) and used to
calculate the true Ki using the relationship
Ki = Ki,app/(1+
[S]/Km), where [S] is the substrate concentration.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
View larger version (18K):
[in a new window]
Fig. 1.
Domain organization of
preprofalcipain-2. The schematic shows locations of a predicted
type II transmembrane domain (TM), the mature protease
domain processing site (arrow), an unusual amino-terminal
extension of the mature protease (filled box), and highly
conserved catalytic amino acids (C, H,
N). The sequence flanking the protease domain-processing
site of falcipain-2 (FP2) was aligned using the Clustal
method (38) with corresponding regions of falcipain-3 (FP3),
papain (Pap), human cathepsin K (hCK), human
cathepsin L (hCL), and cruzain (Cru). Fully
conserved amino acids are shaded red, identities with FP2
are shaded green, protease domain cleavage sites are shown
by arrowheads, the amino-terminal extensions of FP2 and FP3
are underlined, and "ERFNIN" prodomain residues (18) are
labeled with asterisks.
188FP2,
89FP2, and
35FP2)
and mature falcipain-2 alone (FP2) in E. coli (Fig.
2, A and B). Each
of the proteins was refolded at alkaline pH and underwent
autohydrolysis at acid pH to a product of identical size (Fig.
2C). Amino-terminal sequencing of the active products
revealed the native mature falcipain-2 terminus for the FP2 construct
(QMNYEE) and microheterogeneity (DQMNYEE and MNYEE) for the three
prodomain constructs. All four refolded proteins were enzymatically
active, as demonstrated by hydrolysis of the substrates Z-Leu-Arg-AMC
and gelatin (Fig. 2D). The refolding of each construct to
active protein varied with the composition of refolding buffer and
redox couple, as seen previously (8), but optimized recovery for each
product was similar (Fig. 2A). The progress of refolding to
active enzyme for each protein was very similar, with maximum activity
achieved after ~18 h (Fig. 3). Thus, in
contrast to all other described papain-family proteases, the prodomain
of falcipain-2 is not required for folding of the active enzyme.
Furthermore, including the prodomain in expression constructs does not
improve the speed or efficiency of folding over that of the mature
protease.

View larger version (24K):
[in a new window]
Fig. 2.
Expression and folding of falcipain-2
constructs. A, schematic of expressed constructs.
Percentage recovery was calculated as the quantity of active protease
(based on active site titration with Z-Phe-Arg-FMK) divided by the
starting quantity of unfolded protein (quantified by Bradford assay).
Purified recombinant proteins were evaluated by SDS-PAGE before
(B) and after (C) refolding at alkaline pH, and
to assess activity, refolded proteins were also evaluated by
gelatin-substrate SDS-PAGE (D). Gels were stained with
Coomassie Blue. The positions of molecular mass standards are shown in
kilodaltons.

View larger version (18K):
[in a new window]
Fig. 3.
Progress of refolding.
Denatured-reduced recombinant proteins were diluted 100-fold in
refolding buffer containing 1 mM each of reduced and
oxidized glutathione (buffers B for
188FP2 and
188dFP2, C for
89FP2 and
89dFP2, and E for
35FP2, FP2, and dFP2; see
"Experimental Procedures" for description of buffers) and incubated
at 4 °C. Aliquots from each reaction were tested for Z-Leu-Arg-AMC
hydrolysis as described under "Experimental Procedures," and
results are expressed as the percentage of maximum activity
(fluorescence units/min) obtained with any protease.
Effect of the prodomain on the catalytic properties of falcipain-2
188dFP2,
89dFP2) and mature falcipain-2 lacking the 17-amino acid
extension (dFP2) were all incapable of folding to active enzyme in any
of the 176 tested buffers (Fig. 3). Thus, the short amino-terminal
extension of falcipain-2 is required for correct folding of the mature
protease.

View larger version (15K):
[in a new window]
Fig. 4.
Expression of deletion and pro
constructs. Schematic of expressed deletion constructs
(A) and prodomain constructs (B). Percentage
recovery of active protease after refolding of deletion constructs was
calculated as described in Fig. 2. Purified recombinant deletion
(C) and prodomain (D) proteins were analyzed by
SDS-PAGE and Coomassie Blue-staining. The positions of molecular mass
standards are shown in kilodaltons.
188P17,
89P17)
or without (
188P,
89P) the amino-terminal extension were expressed
(Fig. 4, B and D) and incubated with the mature
protease lacking the extension (dFP2) in standard folding buffers (Fig.
5). The extension-deleted mature protease
(dFP2) was successfully folded to active enzyme in combinations that
included extended prodomain constructs (
188P17 or
89P17) but not in those including prodomains without the
extension (
188P,
89P; Fig. 5). Thus, presentation of the amino-terminal extension of mature falcipain-2 in trans was
adequate to mediate correct folding of truncated mature falcipain-2.
When a synthetic peptide identical to the 17-amino acid extension was incubated with the extension-deleted mature protease (dFP2), folding to
active enzyme was not seen (Fig. 5). Our results indicate that the
short amino-terminal falcipain-2 extension does not need to be
covalently bound to the mature protease to mediate folding. However,
the free peptide could not mediate folding, suggesting that, when it is
not bound to the remainder of the mature protease, the extension must
be presented by the prodomain, presumably after this domain binds to
the mature protease via structural features maintained by well
conserved "ERFNIN" and other residues in many papain-family enzymes
(Fig. 1; Refs. 18 and 19).

View larger version (15K):
[in a new window]
Fig. 5.
Proteolytic activity of folded mature and
truncated falcipain-2 constructs. Equal quantities of mature
falcipain-2 (FP2) and extension-deleted falcipain-2
(dFP2) were incubated alone or with prodomain constructs (as
labeled; equimolar concentrations) or a synthetic 17-mer peptide
identical to the falcipain-2 amino-terminal extension (Peptide;
dFP2:peptide ratio of 1:50) in refolding buffer (containing 1 mM each GSH and GSSG). Results represent hydrolysis of
Z-Leu-Arg-AMC by 25 µl of each refolding reaction (arbitrary
fluorescence units) in the optimal refolding buffer for each protein
(buffer E for FP2 and buffer G for dFP2 and all its combinations).
Error bars represent S.D. of the results from four refolding
reactions. FU, fluorescence units.
188FP2,
89FP2,
35FP2, and FP2; Fig.
2). The prodomain was a potent inhibitor of the mature protease, with
similar inhibition constants for each active product (Table
II). Inhibition of the protease was
competitive and reversible, as indicated by very similar
VMAX values but increasing Km
values with increasing prodomain concentrations. For example, the
Km for Z-Leu-Arg-AMC was 8.2 µM
(VMAX, 2.7×10
7 µmol
s
1) in the absence of the prodomain and 73.3 µM (VMAX, 2.7×10
7
µmol s
1) in the presence of 18 nM
prodomain.
Inhibition of falcipain-2 by the prodomain
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Box 0811, University
of California, San Francisco, CA 94143-0811. Tel.: 415-206-8845; Fax:
415-648-8425; E-mail: rosnthl@itsa.ucsf.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Breman, J. G.
(2001)
Am. J. Trop. Med. Hyg.
64,
1-11[Medline]
[Order article via Infotrieve] 2.
Rosenthal, P. J.,
and Miller, L. H.
(2001)
in
Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery
(Rosenthal, P. J., ed)
, pp. 3-13, Humana Press Inc., Totowa, NJ
3.
Olliaro, P. L.,
and Yuthavong, Y.
(1999)
Pharmacol. Ther.
81,
91-110[CrossRef][Medline]
[Order article via Infotrieve] 4.
Rosenthal, P. J.,
McKerrow, J. H.,
Aikawa, M.,
Nagasawa, H.,
and Leech, J. H.
(1988)
J. Clin. Invest.
82,
1560-1566[Medline]
[Order article via Infotrieve] 5.
Rosenthal, P. J.,
Lee, G. K.,
and Smith, R. E.
(1993)
J. Clin. Invest.
91,
1052-1056[Medline]
[Order article via Infotrieve] 6.
Shenai, B. R.,
Sijwali, P. S.,
Singh, A.,
and Rosenthal, P. J.
(2000)
J. Biol. Chem.
275,
29000-29010 7.
Sijwali, P. S.,
Shenai, B. S.,
Gut, J.,
Singh, A.,
and Rosenthal, P. J.
(2001)
Biochem. J.
360,
481-489[CrossRef][Medline]
[Order article via Infotrieve] 8.
Sijwali, P. S.,
Brinen, L. S.,
and Rosenthal, P. J.
(2001)
Protein Expression Purif.
22,
128-134[CrossRef][Medline]
[Order article via Infotrieve] 9.
Smith, S. M.,
and Gottesman, M. M.
(1989)
J. Biol. Chem.
264,
20487-20495 10.
Yamamoto, Y.,
Watabe, S.,
Kageyama, T.,
and Takahashi, S. Y.
(1999)
Arch. Insect Biochem. Physiol.
42,
167-178[CrossRef][Medline]
[Order article via Infotrieve] 11.
Shinde, U.,
and Inouye, M.
(2000)
Semin. Cell Dev. Biol.
11,
35-44[CrossRef][Medline]
[Order article via Infotrieve] 12.
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve] 13.
Barrett, A. J.,
and Kirschke, H.
(1981)
Methods Enzymol.
80,
535-561[Medline]
[Order article via Infotrieve] 14.
Ho, S. N.,
Hunt, H. D.,
Horton, R. M.,
Pullen, J. K.,
and Pease, L. R.
(1989)
Gene
77,
51-59[CrossRef][Medline]
[Order article via Infotrieve] 15.
Salvesen, G.,
and Nagase, H.
(1989)
in
Proteolytic Enzymes: A Practical Approach
(Benyon, R. J.
, and Bond, J. S., eds)
, pp. 87-88, IRL Press at Oxford University Press, Oxford, UK
16.
Berti, P. J.,
and Storer, A. C.
(1995)
J. Mol. Biol.
246,
273-283[CrossRef][Medline]
[Order article via Infotrieve] 17.
Shinde, U. P.,
Liu, J. J.,
and Inouye, M.
(1997)
Nature
389,
520-522[CrossRef][Medline]
[Order article via Infotrieve] 18.
Karrer, K. M.,
Peiffer, S. L.,
and DiTomas, M. E.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3063-3067 19.
Kreusch, S.,
Fehn, M.,
Maubach, G.,
Nissler, K.,
Rommerskirch, W.,
Schilling, K.,
Weber, E.,
Wenz, I.,
and Wiederanders, B.
(2000)
Eur. J. Biochem.
267,
2965-2972[Medline]
[Order article via Infotrieve] 20.
Guay, J.,
Falgueyret, J. P.,
Ducret, A.,
Percival, M. D.,
and Mancini, J. A.
(2000)
Eur. J. Biochem.
267,
6311-6318[Medline]
[Order article via Infotrieve] 21.
Taylor, M. A.,
Baker, K. C.,
Briggs, G. S.,
Connerton, I. F.,
Cummings, N. J.,
Pratt, K. A.,
Revell, D. F.,
Freedman, R. B.,
and Goodenough, P. W.
(1995)
Protein Eng.
8,
59-62 22.
Baker, D.,
Silen, J. L.,
and Agard, D. A.
(1992)
Proteins
12,
339-344[CrossRef][Medline]
[Order article via Infotrieve] 23.
Li, Y., Hu, Z.,
Jordan, F.,
and Inouye, M.
(1995)
J. Biol. Chem.
270,
25127-25132 24.
Frydman, J.
(2001)
Annu. Rev. Biochem.
70,
603-647[CrossRef][Medline]
[Order article via Infotrieve] 25.
Silen, J. L.,
Frank, D.,
Fujishige, A.,
Bone, R.,
and Agard, D. A.
(1989)
J. Bacteriol.
171,
1320-1325 26.
Silen, J. L.,
and Agard, D. A.
(1989)
Nature
341,
462-464[CrossRef][Medline]
[Order article via Infotrieve] 27.
Zhu, X. L.,
Ohta, Y.,
Jordan, F.,
and Inouye, M.
(1989)
Nature
339,
483-484[CrossRef][Medline]
[Order article via Infotrieve] 28.
Ma, B.,
Tsai, C. J.,
and Nussinov, R.
(2000)
Protein Eng.
13,
617-627 29.
Higaki, J. N.,
Evnin, L. B.,
and Craik, C. S.
(1989)
Biochemistry
28,
9256-9263[CrossRef][Medline]
[Order article via Infotrieve] 30.
Venekei, I.,
Graf, L.,
and Rutter, W. J.
(1996)
FEBS Lett.
379,
139-142[CrossRef][Medline]
[Order article via Infotrieve] 31.
Fortenberry, S. C.,
and Chirgwin, J. M.
(1995)
J. Biol. Chem.
270,
9778-9782 32.
Hadley, T.,
Aikawa, M.,
and Miller, L. H.
(1983)
Exp. Parasitol.
55,
306-311[CrossRef][Medline]
[Order article via Infotrieve] 33.
Salmon, B. L.,
Oksman, A.,
and Goldberg, D. E.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
271-276 34.
Raphael, P.,
Takakuwa, Y.,
Manno, S.,
Liu, S. C.,
Chishti, A. H.,
and Hanspal, M.
(2000)
Mol. Biochem. Parasitol.
110,
259-272[CrossRef][Medline]
[Order article via Infotrieve] 35.
Dua, M.,
Raphael, P.,
Sijwali, P. S.,
Rosenthal, P. J.,
and Hanspal, M.
(2001)
Mol. Biochem. Parasitol.
116,
95-99[CrossRef][Medline]
[Order article via Infotrieve] 36.
Francis, S. E.,
Sullivan, D. J.,
and Goldberg, D. E.
(1997)
Annu. Rev. Microbiol.
51,
97-123[CrossRef][Medline]
[Order article via Infotrieve] 37.
Slomianny, C.
(1990)
Blood Cells
16,
369-378[Medline]
[Order article via Infotrieve] 38.
Thompson, J. D.,
Higgins, D. G.,
and Gibson, T. J.
(1994)
Nucleic Acids Res.
22,
4673-4680
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. Martens, K. Vandepoele, and Y. Van de Peer Whole-genome analysis reveals molecular innovations and evolutionary transitions in chromalveolate species PNAS, March 4, 2008; 105(9): 3427 - 3432. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hogg, K. Nagarajan, S. Herzberg, L. Chen, X. Shen, H. Jiang, M. Wecke, C. Blohmke, R. Hilgenfeld, and C. L. Schmidt Structural and Functional Characterization of Falcipain-2, a Hemoglobinase from the Malarial Parasite Plasmodium falciparum J. Biol. Chem., September 1, 2006; 281(35): 25425 - 25437. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. X. Wang, K. C. Pandey, J. R. Somoza, P. S. Sijwali, T. Kortemme, L. S. Brinen, R. J. Fletterick, P. J. Rosenthal, and J. H. McKerrow Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease PNAS, August 1, 2006; 103(31): 11503 - 11508. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Pandey, S. X. Wang, P. S. Sijwali, A. L. Lau, J. H. McKerrow, and P. J. Rosenthal The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif PNAS, June 28, 2005; 102(26): 9138 - 9143. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Pandey, P. S. Sijwali, A. Singh, B.-K. Na, and P. J. Rosenthal Independent Intramolecular Mediators of Folding, Activity, and Inhibition for the Plasmodium falciparum Cysteine Protease Falcipain-2 J. Biol. Chem., January 30, 2004; 279(5): 3484 - 3491. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Nielsen, J. Kasper, M. Choi, T. Bedford, K. Kristiansen, D. F. Wirth, S. K. Volkman, E. R. Lozovsky, and D. L. Hartl Gene Conversion as a Source of Nucleotide Diversity in Plasmodium falciparum Mol. Biol. Evol., May 1, 2003; 20(5): 726 - 734. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||